[{"id":"91477ff8-142f-4402-9532-82ad52403fb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03804944","created_at":"2021-01-18T18:48:24.995Z","updated_at":"2025-02-25T14:01:36.868Z","phase":"Phase 2","brief_title":"Converting HR+ Breast Cancer Into an Individualized Vaccine","source_id_and_acronym":"NCT03804944","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Mobista (CDX-301)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/17/2020","start_date":" 03/17/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-19"},{"id":"7eb5032a-f810-48b6-80fe-022a794eb314","acronym":"","url":"https://clinicaltrials.gov/study/NCT05029999","created_at":"2021-09-01T14:53:00.539Z","updated_at":"2024-07-02T16:34:26.023Z","phase":"Phase 1","brief_title":"CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer","source_id_and_acronym":"NCT05029999","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin • CDX-1140 • Mobista (CDX-301)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/20/2022","start_date":" 04/20/2022","primary_txt":" Primary completion: 04/20/2025","primary_completion_date":" 04/20/2025","study_txt":" Completion: 04/20/2025","study_completion_date":" 04/20/2025","last_update_posted":"2024-06-14"},{"id":"e67b207c-524d-4340-9a2e-5cbef643f117","acronym":"","url":"https://clinicaltrials.gov/study/NCT04616248","created_at":"2021-01-19T20:33:34.730Z","updated_at":"2024-07-02T16:35:26.987Z","phase":"Phase 1","brief_title":"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors","source_id_and_acronym":"NCT04616248","lead_sponsor":"University of Southern California","biomarkers":" HER-2","pipe":" | ","alterations":" PD-L1 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDX-1140 • Hiltonol (poly-ICLC) • Mobista (CDX-301)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/09/2023","start_date":" 01/09/2023","primary_txt":" Primary completion: 01/09/2025","primary_completion_date":" 01/09/2025","study_txt":" Completion: 01/09/2026","study_completion_date":" 01/09/2026","last_update_posted":"2023-12-06"},{"id":"b8b377f8-f74b-4e8e-8bac-28bf811e0fc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02129075","created_at":"2021-01-18T09:52:16.035Z","updated_at":"2024-07-02T16:36:20.676Z","phase":"Phase 2","brief_title":"A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma","source_id_and_acronym":"NCT02129075","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CTAG1B • CD4 • PRAME","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B • CD4 • PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • Mobista (CDX-301) • Neo Vax (NEO-PV-01) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 04/09/2014","start_date":" 04/09/2014","primary_txt":" Primary completion: 03/28/2016","primary_completion_date":" 03/28/2016","study_txt":" Completion: 05/18/2018","study_completion_date":" 05/18/2018","last_update_posted":"2021-11-16"}]